Bavarian Nordic A/S  announced today that the Public Health Agency of Canada (PHAC) has ordered IMVAMUNE® smallpox vaccine to the national stockpile at a total value of USD 31.2 million. Deliveries...

Bavarian Nordic A/S announced today that Health Canada has expanded the approval of the Company’s non-replicating smallpox vaccine, IMVAMUNE® to include additional indications – specifically, monkeypox...

Officials from Bavarian Nordic yesterday announced the results of a successful Phase 3 clinical trial led by USAMRIID that demonstrated the safety and efficacy of the company’s investigational, non-replicating...

Biopharmaceutical manufacturer Bavarian Nordic announced on May 13th that significant progress was achieved in demonstrating two versions of its smallpox vaccine, Imvamune, offer satisfactory protection...